CHMP recommends label expansion for Eliquis

Europe's Committee for Medicinal Products for Human Use (CHMP) recommends that the European Medicines Agency (EMA) approve Bristol-Myers Squibb's (BMY) Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE in adults.

Eliquis is an oral selective Factor Xa inhibitor, a key blood clotting protein. It decreases thrombin generation and blood clot formation. It is currently approved the U.S., E.U., Japan and other countries as a treatment to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is approved for the prophylaxis of DVT which can lead to PE in adult patients who have undergone hip or knee replacement surgery in the U.S. and E.U. and other countries (except Japan).

From other sites
Comments (1)
  • Benyas
    , contributor
    Comments (84) | Send Message
    BMY has had three exciting announcements in the past 48 hours; concerning Eliquis, Daclinza, and Nivolumab. If I have made spelling errors it is because I am excited. Can anyone explain to me why the stock has dropped in price for the past two days?
    27 Jun 2014, 06:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs